AVADEL PHARMACEUTICALS PLC — Director's Dealing 2023

Jun 6, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2023-06-05

Reporting Person: Divis Gregory J (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-05	Stock Option (Right to Buy)	$4.69	A	350000	Acquired	2032-08-04	ADSs (350000)	Direct

Footnotes

F1: On August 4, 2022, the Reporting Person was granted an option to purchase 350,000 ADSs, for which vesting was subject to the satisfaction of certain performance criteria. The performance criteria were met on June 5, 2023 (the "First Vesting Date"), resulting in the vesting of 50% of the ADSs underlying such option. The remaining ADSs will vest on the one year anniversary of the First Vesting Date, subject to the Reporting Person's continued service at such time.

F2: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.